A Pilot, Phase I, 2-Period, Fasting, Bioavailability, Safety and PK [pharmacokinetic] Study Evaluating A Single Dose Intravenous Fentanyl 200 microg) and Single Doses of 2 or 3 mL AeroLEF (Liposome-Encapsulated Fentanyl 500 microg/mL) in Normal Healthy Non-Smoking Subjects

Trial Profile

A Pilot, Phase I, 2-Period, Fasting, Bioavailability, Safety and PK [pharmacokinetic] Study Evaluating A Single Dose Intravenous Fentanyl 200 microg) and Single Doses of 2 or 3 mL AeroLEF (Liposome-Encapsulated Fentanyl 500 microg/mL) in Normal Healthy Non-Smoking Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 26 Jul 2008

At a glance

  • Drugs Fentanyl; Fentanyl
  • Indications Cancer pain; Postoperative pain
  • Focus Adverse reactions
  • Sponsors YM BioSciences
  • Most Recent Events

    • 26 Jul 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top